Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv
Authors:
Open Access
- 24 October 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (12) , 1466-1476
Abstract
In this pharmacoeconomic simulation, we: (1) modeled the cost-efficiency of converting patients from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv for prophylaxis of chemotherapy-induced...Keywords
Funding Information
- Coherus BioSciences, Inc.
This publication has 32 references indexed in Scilit:
- Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancerTherapeutic Advances in Medical Oncology, 2012
- Biosimilars—why terminology mattersNature Biotechnology, 2011
- Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropeniaJournal of Oncology Pharmacy Practice, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibioticsCritical Reviews in Oncology/Hematology, 2009
- Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic ReviewJournal of Clinical Oncology, 2007
- Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III StudyJournal of Clinical Oncology, 2005
- First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III StudyJournal of Clinical Oncology, 2005
- CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trialBlood, 2003
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal of Cancer, 1993